Navigation Links
Hebrew University researchers discover expanded role for cancer-causing gene
Date:11/8/2010

Jerusalem, November 7, 2010 Researchers at the Hebrew University of Jerusalem have discovered that Vav1 an oncogene (cancer-causing gene) found in recent years to be one of the factors in tumorous tissue growth -- plays a wider role in several types of cancer than had previously been thought. The discovery has implications for further concentration on targeting this gene in cancer research.

The work of the researchers, led by Dr. Shulamit Katzav-Shapira of the Institute for Medical Research Israel-Canada at the Hebrew University of Jerusalem Faculty of Medicine, was published recently in the Journal of Biological Chemistry.

Vav1 has been known to be involved in alterations in gene expression in the immune system, where it is physiologically expressed. Vav1 was discovered a few years ago by Katzav-Shapira when she was working in the National Cancer Institute laboratory of Dr. Mariano Barbacid in the US. Since this newly identified gene represented the sixth oncogene detected in Dr. Barbacid's laboratory, it was designated by Katzav-Shapira as Vav (six in Hebrew) 1.

Vav1 is involved in the process whereby cells are "triggered" into action. When receptors on the surface of a cell, known as growth factor receptors, receive signals for growth, they relay this information into the cell. This chain of command is often called a "signal transduction cascade" or a "pathway." Signal transduction cascades play a fundamental role in controlling normal cell proliferation, differentiation, cell adhesion, spontaneous movement, and programmed cell death.

Mutations in the proteins driving this signal transduction process are among the main causes for driving cells to develop into cancer. Thus, identification of the signal transducers that are involved in malignant transformation is a prerequisite for understanding cancer and improving its diagnosis and treatment. Since Vav1 was shown to be involved in events leading to alterations in gene expression in the immune system, it is a "key player" in this process.

Now, mutated Vav1 has been shown by Dr. Katzav-Shapira and others to be highly expressed also in neuroblasoma (a cancer that forms in nerve tissue), pancreatic and lung cancer. Indeed, it was surprisingly found to be expressed in 44% of malignant human lung cancer tissue samples that were studied. Since, say the researchers, Vav1 has now been shown to play a role in the process of abnormal tissue growth in several human cancers, it has become an even more highly important potential therapeutic target for cancer therapy.


'/>"/>

Contact: Jerry Barach
jerry@savion.huji.ac.il
972-258-82904
The Hebrew University of Jerusalem
Source:Eurekalert  

Related medicine news :

1. Collagen manufactured from transgenic tobacco plants at Hebrew University
2. Hebrew University added to Singapore research program
3. University of Virginia Health System Medical Laboratories Selects Sunquest's Specimen Collection Solution
4. Akron Institute of Herzing University Launches Its First Bachelors Degree Programs to Prepare Students for Even Greater Success in Business, Health Care and IT
5. Most pandemic plans in Ontario hospitals have not been tested: Queens University study
6. San Diego State University and BIOCOM Institute Receive $4.95 Million Grant: The BRIDGE Project, Linking Education to Employment in San Diegos Life Sciences Industry
7. Smithsonian Institution, Arizona State University announce education and research partnership
8. Untreated poor vision in elderly linked to dementia, University of Michigan study shows
9. Giarmarco, Mullins & Horton, P.C. President Joseph F. Page to Speak at University of Michigan
10. Arizona State Universitys Decision Theater offers balance to an off-kilter world
11. Forest City Announces Joint Venture with Health Care REIT for University Park Life Science Properties
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Hebrew University researchers discover expanded role for cancer-causing gene
(Date:5/25/2016)... ... May 25, 2016 , ... ... it will join America's leading engineers at the American Society of Safety Engineers ... World Congress Center. , Engineers, speakers and exhibitors from more than 40 ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... its inaugural health care blockchain event, Distributed: Health, to be held in Nashville, ... downtown Symphony Center. , A 24-hour Hackathon preceding the event will host teams ...
(Date:5/24/2016)... ... May 24, 2016 , ... i2i, a national leader in ... its “Transforming Outcomes” User Conference in Las Vegas on May 19-20, 2016. ... set the market standard for meaningful population health management. The company recently ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... Center at Sentara Northern Virginia Medical Center located in Woodbridge, VA. The ... surgical services into a single site. , The new 2 story building houses ...
(Date:5/24/2016)... Irvine, CA — , ... ... the appointment of three new members of its Advisory Board. ... Chico and Sarah Kusch. “All three of them embody the mission ... team. We are very fortunate to have them as we continue ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... 2016 ReportsnReports.com adds "Chronic ... that provides an overview on therapeutic pipeline of ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Chronic Cough ...
(Date:5/24/2016)... HENDERSON, Nev. , May 24, 2016  Diana ... painfully "eats" her organs from the inside out.  This ... her completely dependent on her children and grandchildren to ... of her wheelchair, Diana,s family cannot haul the wheelchair.  ... rides in the car, and Diana is left to ...
(Date:5/24/2016)... , May 24, 2016 ... the world , s first dual ... fistula intervention   OrbusNeich, a global company ... expanded its portfolio to include products to treat peripheral ... the company,s first entry devices for lower limb and ...
Breaking Medicine Technology: